0% found this document useful (0 votes)
3 views15 pages

Sars 2025

Uploaded by

lanavij470
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
3 views15 pages

Sars 2025

Uploaded by

lanavij470
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Severe Acute Respiratory Syndrome

(SARS)

Dr. Navin Kumar Chaudhary


Professor
Dept. of Microbiology, CMC-TH Bharatpur, Nepal
2nd March 2025
Human Coronavirus
• Human coronaviruses were first identified in the mid-1960s
• Coronaviruses (CoV) are a large family of viruses that cause
illness ranging from the common cold to more severe
diseases such as
– Middle East Respiratory Syndrome (MERS-CoV)
– Severe Acute Respiratory Syndrome (SARS-CoV)
– A novel coronavirus (nCoV) / COVID-19
• New strain that has not been previously identified in humans

Coronaviruses are
named for the crown-like
spikes on their surface
Human Coronavirus Types
• Four main sub-group: alpha, beta, gamma, and delta
• The seven coronaviruses that can infect human are:
• Common human coronaviruses
– 229E (alpha coronavirus)
– NL63 (alpha coronavirus)
– OC43 (beta coronavirus)
– HKU1 (beta coronavirus)
• Other human coronaviruses
– MERS-CoV (beta coronavirus that causes MERS)
– SARS-CoV (beta coronavirus that causes SARS)
– SARS-CoV-2 (novel coronavirus that causes coronavirus
disease 2019, or COVID-19
Human Coronavirus Types
• Some times coronaviruses that infect animals can evolve
and make people sick and become a new human coronavirus
• Three recent examples of this are 2019-nCoV, SARS-CoV,
and MERS-CoV
SARS
Mid-November 2002
• Guangdong Province, China
“ Outbreak of atypical pneumonia”
• First SARS case: 16th Nov, 2002

11 February 2003
• WHO informed
• 305 cases, 5 deaths
• 30% of health care workers

July 2003
• Worldwide, 8,450 cases, 810 deaths in 33 countries
• Major foci in China, SE Asia, and Toronto
Epidemiology
• Cause : SARS associated Coronavirus (SARS-CoV)

• Means of transmission
Evidence of person-to-person transmission
Close contact with body fluids (especially respiratory droplets)
Contaminated hands, clothes, equipment, environment

• Incubation period: 2 –10 days

• Organism survival in the environment


– Duration unknown
6
– Other coronavirus are known to survive for up to 4 hours
SARS associated Coronavirus ( SARS-CoV)
• Family: Coronaviridae
• Genus: Coronaviruses
• Species: Human Coronavirus (CoV)
• Strain: SARS-CoV
• The virions are about 100 - 140 nm in diameter
• Pleomorphic and enveloped particles
 Characteristic long projected surface protein (spike)
about 20 nm long, Membrane glycoprotein, Envelope
protein
 The non-segmented, Positive-sense, single-stranded
RNA, linear 29,727 nucleotides long (largest RNA
genome), size ranging from 27 to 32 kb
Replication
•Viral entry: Binds by using spike proteins
•Enters either by membrane fusion or receptor-mediated
endocytosis
•ssRNA used to create (-) ssRNA in cytoplasm
•Has its own RNA poly (-) strand that forms a replication
complex attached to the membrane Complex produces new
genomic RNAs and sub genomic mRNAs; and mRNAs code
for N, M & S
•Ribonucleoproteins form from N + genomic RNA
Ribonucleoproteins attach to S & M proteins at the membrane,
This complex comes detached into the lumen (immature
virion)
•Mature as they progress through the periphery of the Golgi
apparatus and become denser and more icosahedral & Buds off
Replication
SARS natural hosts
• Natural reservoir host: Horseshoe bats

[Link]/. ../images/[Link] [Link]/bats/rusbats/ pictures/[Link]

• Direct human infection is not likely to occur


• Possibly the virus can jump to intermediate animals such as
the civet and adapt in such a way that it can infect humans

•Masked palm civets (Paguma larvata)


Suspect SARS Case Case Definitions
• High fever >38 0C
• One or more respiratory symptoms including:
• Cough
• Shortness of breath or breathing difficulty
• One or more of the following:
• Close contact, within 10 days before the onset of symptoms with
a person diagnosed with SARS
• History of travel, within 10 days before onset of symptoms to an
affected area
Probable Case: A suspect case with chest X-ray findings consistent
with pneumonia or respiratory distress syndrome (RDS) OR A
suspect case with an unexplained illness resulting in death, with
autopsy examination demonstrating the pathology of RDS without
an identifiable cause

Close contact: having cared for, lived with, or had direct contact with the respiratory secretions or body
fluids of a suspect or probable case of SARS; Affected area: an area in which local chain(s) of11
transmission of SARS is/are occurring as reported by the national public health authorities
Symptoms
• Clinical course:
•Short incubation period (6 days/2 -10 days)

•Intensive care usually requires about10 days


after the onset of symptoms
•There are generally 3 phases: [Link]/
images/center/sars_flu.jpg

•Week 1: Cold-like symptoms, fever, myalgia, chill, and a sore throat


•Week 2: Recurrence of fever, Onset diarrhea, and oxygen desaturation
•Only 20% of patients reach this phase, which requires ventilator support
•The fatality rate is about 10% upon infection

Breathing difficulties 3-7 days


Sudden onset of high fever (>38°C) & dry cough Chills and shivering & muscle aches from the onset of symptoms
Clinical picture in SARS patients

Exposure to SARS Fever, myalgia, dry non-productive cough Recovery


cough, headache shortness of breath approx
(early symptoms) 90%
Incubation period Prodrome Lower respiratory
phase

~2 to 10 days ~ 1- to 2 days From day 4 onwards Acute


up to 13 days respiratory
reported distress
syndrome
approx 10%
Infectivity

None /very low Low Very high

13
Diagnosis of SARS
• Clinical characteristics of illness

• Epidemiologic link to SARS, i.e., travel or contact

• Laboratory evidence of SARS-CoV infection

• Detection of virus:
– EM in clinical specimens (CoV-like particles)

– Isolation of virus

– Detection of viral antigens: IFA or ELISA for respiratory specimens

– Detection of viral RNA: Reverse Transcription-PCR

• Detection of SARS-specific antibody

– IFA, ELISA, Neutralization


THANK YOU

You might also like